The short version of 垂体受体 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-22. Anything still debated is marked as such rather than presented as settled.
研究背景集中在特定人群的体成分改变,尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致,部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题,现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽,序列与内源性生长激素释放激素(GHRH)的 1-44 片段一致,区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割,从而延长分子在循环中的存留时间。作为肽类分子,它难以经胃肠道吸收,文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物,以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶,升高细胞内 cAMP,再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点,生长激素仍以脉冲方式分泌,而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生,构成完整的生长激素轴响应。
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
| 性质 | 取值 | 备注 |
|---|---|---|
| 分子类型 | 合成四十四肽 | GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 延缓酶切 |
| 分子量 | 约 5135 Da | 依序列与修饰 |
| 受体靶点 | 垂体 GHRH 受体 | 经 cAMP 通路 |
| 常见同义名 | GHRH(1-44) 类似物 | 文献通用称法 |
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
The developer of the Half-Life series, Valve, was founded in 1996 in Kirkland, Washington by the former Microsoft employees Mike Harrington and Gabe Newell. Valve began working on the first Half-Life soon after formation, and settled on a concept for a horror-themed 3D action game, using the Quake engine as licensed by id Software. The game was a hit at the 1997 E3 convention, where its animation system and artificial intelligence were demonstrated. The success led to its first expansion pack, Half-Life: Opposing Force, which was developed by Gearbox Software, a new company based in Plano, Texas, and announced on April 15, 1999. The Gearbox founder, Randy Pitchford, said Valve gave them the project to allow Valve to focus on future games. Opposing Force was demonstrated at the 1999 E3 convention, where new locations, characters and the story were revealed. The second Half-Life expansion pack, Half-Life: Blue Shift, was again developed by Gearbox Software and announced by its publisher, Sierra Entertainment, on August 30, 2000. Sierra intended to release Blue Shift for the Dreamcast, and it was set to include higher detail models and textures that were double the polygon count of the models from Half-Life. However, after several months of delays, Sierra terminated the Dreamcast version of Blue Shift on June 16, 2001, and instead released it for Windows on June 12. Afterward, Gearbox began working on a Half-Life game for the PlayStation 2.
In the case of prolactin and leptin, there is evidence of active uptake at the choroid plexus from the blood into the cerebrospinal fluid (CSF). Some pituitary hormones have a negative feedback influence upon hypothalamic secretion; for example, growth hormone feeds back on the hypothalamus, but how it enters the brain is not clear. There is also evidence for central actions of prolactin. Findings have suggested that thyroid hormone (T4) is taken up by the hypothalamic glial cells in the infundibular nucleus/ median eminence, and that it is here converted into T3 by the type 2 deiodinase (D2). Subsequent to this, T3 is transported into the thyrotropin-releasing hormone (TRH)-producing neurons in the paraventricular nucleus. Thyroid hormone receptors have been found in these neurons, indicating that they are indeed sensitive to T3 stimuli. In addition, these neurons expressed MCT8, a thyroid hormone transporter, supporting the theory that T3 is transported into them. T3 could then bind to the thyroid hormone receptor in these neurons and affect the production of thyrotropin-releasing hormone, thereby regulating thyroid hormone production. The hypothalamus functions as a type of thermostat for the body. It sets a desired body temperature, and stimulates either heat production and retention to raise the blood temperature to a higher setting or sweating and vasodilation to cool the blood to a lower temperature. All fevers result from a raised setting in the hypothalamus; elevated body temperatures due to any other cause are classified as hyperthermia.
==== The Scout Association (United Kingdom) ==== The Scout Association refers to WOSM's emblem as its "Membership Award" and uses it as its joining badge for its Beavers, Cubs, Scouts, Explorer Scouts and Scout Network, with progressing requirements intended to help the member understand their commitment.
== Athletic career == Maroon has competed in 8 Ironman Triathlons (Hawaii – 1993, 2003, 2008, 2010, 2013; Canada – 1995; New Zealand – 1997; Germany – 2000) and is to this day an active triathlon athlete. Dr. Maroon was inducted into the Lou Holtz Upper Ohio Valley Hall of Fame in 1999, the Western Chapter of the Pennsylvania Sports Hall of Fame in 2009 and in 2010 also to the National Fitness Hall of Fame in Chicago. For 2016, in the global ranking of Ironman athletes, Maroon ranks in 4th place in his age group. In 2022, Maroon placed second in the National Senior Games for his age group and placed first in the Chicago Triathlon for his age group.
=== Amino acid basic structure === The general structure of the standard amino acids includes a primary amino group, a carboxyl group and the functional group attached to the α-carbon. The different amino acids are identified by the functional group. As a result of the three different groups attached to the α-carbon, amino acids are asymmetrical molecules. For all standard amino acids, except glycine, the α-carbon is a chiral center. In the case of glycine, the α-carbon has two hydrogen atoms, thus adding symmetry to this molecule. With the exception of proline, all of the amino acids found in life have the L-isoform conformation. Proline has a functional group on the α-carbon that forms a ring with the amino group.
Sources: en.wikipedia.org
In the most expensive political campaign in Vermont's history, Sanders defeated businessman Rich Tarrant by an almost 2-to-1 margin. Many national media outlets projected him as the winner just after the polls closed, before any returns came in.
Jake Austin Walker as Henry King Jr. (season 1; guest season 2):A student at Blue Valley High as well as its star football player. He later develops psionic powers after experiencing emotional distress following his father becoming comatose. His deceased mother was Sylvester Pemberton's sister Merry. Meg DeLacy as Cindy Burman / Shiv:The daughter of the Dragon King, girlfriend of Henry King Jr. and the most popular student at Blue Valley High with enhanced abilities and wields wrist blades from her skin. While she is the school's cheerleading captain, she is determined to follow in her father's footsteps. In pursuit of this, she acquired a powerful suit of armor and a flame-throwing staff. In the second season, she teams up with Eclipso and forms a new ISA called Injustice Unlimited. In the third and final season, she wants to change her ways and joins the new JSA. Later, Cindy starts to manifest a reptilian form due to her father's experiments on her throughout her childhood. Neil Jackson as Jordan Mahkent / Icicle (season 1; recurring season 3; guest season 2):The leader of the Injustice Society of America (ISA), an "astute" businessman with the power of cryokinesis and founder of a firm called The American Dream that is responsible for the revitalization of Blue Valley. Jackson initially thought "Icicle" was "a silly name" and made the character sound "like a My Little Pony", but Johns' pitch helped make the character credible for Jackson. In the third and final season, Icicle had spent the following year reconstituting himself after he was shattered by Mike Dugan.
=== Timber === Blue gum timber is yellow-brown, fairly heavy, with an interlocked grain, and is difficult to season. It has poor timber quality due to growth stress problems, but can be used in construction, fence posts and poles.
Historically, the Wernicke-Kleist-Leonhard school considered periodic catatonia a distinct form of "non-system schizophrenia", characterized by recurrent acute phases with hyperkinetic and akinetic features and often psychotic symptoms. There is also a residual state between these phases, characterized by low-level catatonic features and abulia of varying severity.
Sources: en.wikipedia.org
tesamorelin 属 GHRH 类似物,作用于垂体受体以促进内源生长激素释放;生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。
作为多肽,它难以通过胃肠道吸收,通常需要注射给药。口服会因消化酶降解而失去活性,因此文献中讨论的都是注射途径。
公开研究多集中在内脏脂肪、体成分分布以及与生长激素轴相关的代谢指标。长期安全性和在普通人群中的适用性尚缺乏一致结论。
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.